In this week’s special Q&A episode, John Stanford tackles your biggest questions from around the biotech and policy world. From the growing list of drug price controls under the IRA to the newly announced 15% EU tariffs on medicines, there's a lot at stake for patients, companies, and innovation. John also breaks down the temporary NIH funding freeze, what it means for research, and why August recess matters more than you think.What impact do you think drug price controls will have on innovation?Should medicines be included in international tariff negotiations?What policies should Congress prioritize this fall?📱If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more:https://x.com/MakingMedPodhttps://www.instagram.com/makingmedicinepod/https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=trueTimestamps:0:00 Tech setup and behind-the-scenes3:37 Welcome to the Making Medicine Podcast4:16 Breaking news: FDA's SBER director steps down4:58 Are we moving toward more price controls on drugs?7:47 New EU trade deal and tariffs on pharmaceuticals10:08 How the IRA continues to impact the investment environment12:31 Did the White House freeze NIH funding?15:10 What is August recess and why it matters16:53 Final thoughts and call for listener questions

Ver todos los episodios